(Q60912033)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30635584%20AND%20SRC:MED&resulttype=core&format=json

18 April 2020

title

Sensitivity to splicing modulation of BCL2 family genes defines cancer therapeutic strategies for splicing modulators (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30635584%20AND%20SRC:MED&resulttype=core&format=json

18 April 2020

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30635584%20AND%20SRC:MED&resulttype=core&format=json

18 April 2020

author name string

Daniel Aird

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30635584%20AND%20SRC:MED&resulttype=core&format=json

18 April 2020

Teng Teng

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30635584%20AND%20SRC:MED&resulttype=core&format=json

18 April 2020

Chia-Ling Huang

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30635584%20AND%20SRC:MED&resulttype=core&format=json

18 April 2020

Ermira Pazolli

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30635584%20AND%20SRC:MED&resulttype=core&format=json

18 April 2020

Deepti Banka

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30635584%20AND%20SRC:MED&resulttype=core&format=json

18 April 2020

Kahlin Cheung-Ong

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30635584%20AND%20SRC:MED&resulttype=core&format=json

18 April 2020

Cheryl Eifert

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30635584%20AND%20SRC:MED&resulttype=core&format=json

18 April 2020

Craig Furman

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30635584%20AND%20SRC:MED&resulttype=core&format=json

18 April 2020

Zhenhua Jeremy Wu

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30635584%20AND%20SRC:MED&resulttype=core&format=json

18 April 2020

Michael Seiler

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30635584%20AND%20SRC:MED&resulttype=core&format=json

18 April 2020

Silvia Buonamici

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30635584%20AND%20SRC:MED&resulttype=core&format=json

18 April 2020

Peter Fekkes

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30635584%20AND%20SRC:MED&resulttype=core&format=json

18 April 2020

Craig Karr

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30635584%20AND%20SRC:MED&resulttype=core&format=json

18 April 2020

Eunice Park

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30635584%20AND%20SRC:MED&resulttype=core&format=json

18 April 2020

Peter G Smith

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30635584%20AND%20SRC:MED&resulttype=core&format=json

18 April 2020

Lihua Yu

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30635584%20AND%20SRC:MED&resulttype=core&format=json

18 April 2020

Yoshiharu Mizui

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30635584%20AND%20SRC:MED&resulttype=core&format=json

18 April 2020

Markus Warmuth

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30635584%20AND%20SRC:MED&resulttype=core&format=json

18 April 2020

Agustin Chicas

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30635584%20AND%20SRC:MED&resulttype=core&format=json

18 April 2020

Laura Corson

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30635584%20AND%20SRC:MED&resulttype=core&format=json

18 April 2020

Ping Zhu

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30635584%20AND%20SRC:MED&resulttype=core&format=json

18 April 2020

language of work or name

English

0 references

publication date

11 January 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30635584%20AND%20SRC:MED&resulttype=core&format=json

18 April 2020

published in

Nature Communications

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30635584%20AND%20SRC:MED&resulttype=core&format=json

18 April 2020

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30635584%20AND%20SRC:MED&resulttype=core&format=json

18 April 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30635584%20AND%20SRC:MED&resulttype=core&format=json

18 April 2020

page(s)

137

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30635584%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution 4.0 International

18 April 2020

copyright license

start time

11 January 2019

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

describes a project that uses

ImageQuant

1 reference

11 June 2022

https://www.ebi.ac.uk/europepmc/webservices/rest/PMC6329755/fullTextXML

inferred from PubMed Central ID database lookup

limma

1 reference

22 June 2022

https://europepmc.org/article/PMC/6329755

inferred from PubMed Central ID database lookup

exact match

https://scigraph.springernature.com/pub.10.1038/s41467-018-08150-5

0 references

cites work

A blueprint for advancing genetics-based cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-08150-5

7 January 2021

Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-08150-5

7 January 2021

Biomarker development in the precision medicine era: lung cancer as a case study.

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-08150-5

7 January 2021

Combine and conquer: challenges for targeted therapy combinations in early phase trials.

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-08150-5

7 January 2021

Prospects for combining targeted and conventional cancer therapy with immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-08150-5

7 January 2021

Combined vemurafenib and cobimetinib in BRAF-mutated melanoma

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-08150-5

7 January 2021

Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-08150-5

7 January 2021

Frequent pathway mutations of splicing machinery in myelodysplasia

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-08150-5

7 January 2021

Therapeutic targeting of splicing in cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-08150-5

7 January 2021

Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types.

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-08150-5

7 January 2021

Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-08150-5

7 January 2021

Targeting splicing abnormalities in cancer.

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-08150-5

7 January 2021

H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers.

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-08150-5

7 January 2021

MYC regulates the core pre-mRNA splicing machinery as an essential step in lymphomagenesis

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-08150-5

7 January 2021

The spliceosome is a therapeutic vulnerability in MYC-driven cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-08150-5

7 January 2021

Genome-wide RNAi screens in human brain tumor isolates reveal a novel viability requirement for PHF5A

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-08150-5

7 January 2021

Splicing modulators act at the branch point adenosine binding pocket defined by the PHF5A-SF3b complex.

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-08150-5

7 January 2021

Splicing factor SF3b as a target of the antitumor natural product pladienolide.

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-08150-5

7 January 2021

Chemical perturbation of Mcl-1 pre-mRNA splicing to induce apoptosis in cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-08150-5

7 January 2021

The SF3B1 inhibitor spliceostatin A (SSA) elicits apoptosis in chronic lymphocytic leukaemia cells through downregulation of Mcl-1.

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-08150-5

7 January 2021

Regulation of HPV16 E6 and MCL1 by SF3B1 inhibitor in head and neck cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-08150-5

7 January 2021

Biological validation that SF3b is a target of the antitumor macrolide pladienolide

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-08150-5

7 January 2021

Identification of SAP155 as the Target of GEX1A (Herboxidiene), an Antitumor Natural Product

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-08150-5

7 January 2021

Utilization of host SR protein kinases and RNA-splicing machinery during viral replication

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-08150-5

7 January 2021

Selective degradation of splicing factor CAPERα by anticancer sulfonamides

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-08150-5

7 January 2021

Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15.

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-08150-5

7 January 2021

Apoptosis: a review of programmed cell death

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-08150-5

7 January 2021

Apoptosis and cancer: the genesis of a research field

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-08150-5

7 January 2021

The BCL-2 protein family: opposing activities that mediate cell death

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-08150-5

7 January 2021

Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-08150-5

7 January 2021

BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition.

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-08150-5

7 January 2021

Pan-cancer patterns of somatic copy number alteration

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-08150-5

7 January 2021

Chemical genomics identifies small-molecule MCL1 repressors and BCL-xL as a predictor of MCL1 dependency

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-08150-5

7 January 2021

ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-08150-5

7 January 2021

Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-08150-5

7 January 2021

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-08150-5

7 January 2021

Aberrant alternative splicing is another hallmark of cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-08150-5

7 January 2021

Generation 2.5 antisense oligonucleotides targeting the androgen receptor and its splice variants suppress enzalutamide-resistant prostate cancer cell growth

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-08150-5

7 January 2021

Antisense oligonucleotides in cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-08150-5

7 January 2021

Differential GC Content between Exons and Introns Establishes Distinct Strategies of Splice-Site Recognition

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-08150-5

7 January 2021

Hallmarks of Cancer: The Next Generation

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-08150-5

7 January 2021

From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-08150-5

7 January 2021

BCL2 Inhibitors as Anticancer Drugs: A Plethora of Misleading BH3 Mimetics

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-08150-5

7 January 2021

Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi Screening

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-08150-5

7 January 2021

Defining a Cancer Dependency Map.

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-08150-5

7 January 2021

Synergistic drug combinations for cancer identified in a CRISPR screen for pairwise genetic interactions

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-08150-5

7 January 2021

Selective inhibitors of Bcl-2 and Bcl-xL: Balancing antitumor activity with on-target toxicity

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-08150-5

7 January 2021

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-08150-5

7 January 2021

Cancer-Associated SF3B1 Hotspot Mutations Induce Cryptic 3' Splice Site Selection through Use of a Different Branch Point

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-08150-5

7 January 2021

Single-vector inducible lentiviral RNAi system for oncology target validation

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-08150-5

7 January 2021

The pINDUCER lentiviral toolkit for inducible RNA interference in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1038%2FS41467-018-08150-5

7 January 2021

10.1038/S41467-018-08150-5

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30635584%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

18 April 2020

ADS bibcode

2019NatCo..10..137A

0 references

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30635584%20AND%20SRC:MED&resulttype=core&format=json

18 April 2020

1 reference